Intranasal corticosteroids (INCS), oral antihistamines (POAH), and allergen-specific immunotherapy (ASIT) are widely used in the treatment of allergic rhinitis (AR); however, appraisal of treatment effect has been heterogenous, and few studies have interpreted these outcomes in context with measures of nasal airflow.
Objective
To provide a systematic review and meta-analysis of randomized placebo-controlled trials for common therapy classes for AR to assess standardized treatment effect on validated patient-reported outcomes and physiologic measures of airflow.
Methods
A systematic search was performed in PubMed, Scopus, OVID, and Cochrane library databases to identify randomized controlled trials meeting inclusion criteria. Treatment effects of INCS, POAH, and ASIT on total nasal symptom score (TNSS), visual analog scale (VAS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), and peak nasal inspiratory flow (PNIF) were analyzed by meta-analysis.
Results
Twenty-two studies with 4673 AR patients were identified, with 5 INCS, 8 POAH, and 9 ASIT trials. INCS improved TNSS (mean difference [MD] 0.90; P = .002) and PNIF (MD 13.31 L/min [P = .0007]. POAH improved quality of life assessed by RQLQ [MD 0.36; P < .001], but no improvement was found in PNIF. ASIT improved RQLQ [MD 0.65; P < .001], with a trend toward improvement in TNSS.
Conclusion
Overall, INCS resulted in a clinically and statistically meaningful improvement in symptom scores and physiologic measures in AR. POAH and ASIT both improved symptom scores and quality of life, but their impacts upon nasal airflow are uncertain. There is a lack of studies assessing the effect of INCS on quality of life and the effect of POAH on symptom severity, particularly for mild AR. Future studies should assess the effect of treatment for each of these patient-reported measures.
BrożekJLBousquetJAgacheI, et al.Allergic rhinitis and its impact on asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958. doi:10.1016/j.jaci.2017.03.050
2.
BousquetJKhaltaevNCruzAA, et al.Allergic rhinitis and its impact on asthma (ARIA) 2008*. Allergy. 2008;63(s86):8–160. doi:10.1111/j.1398-9995.2007.01620.x
3.
BousquetJAntoJMBachertC, et al.Allergic rhinitis. Nat Rev Dis Primers. 2020;6(1):95. doi:10.1038/s41572-020-00227-0
4.
WallaceDVDykewiczMSBernsteinDI, et al.The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 Supplement):S1–S84. doi:10.1016/j.jaci.2008.06.003
5.
BousquetJSchünemannHJTogiasA, et al.Next-generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on grading of recommendations assessment, development and evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70–80.e3. doi:10.1016/j.jaci.2019.06.049
6.
Van CauwenbergePBachertCPassalacquaG, et al.Consensus statement* on the treatment of allergic rhinitis. Allergy. 2000;55(2):116–134. doi:10.1034/j.1398-9995.2000.00526.x
7.
MortuaireGMichelJPaponJF, et al.Specific immunotherapy in allergic rhinitis. Eur Ann Otorhinolaryngol Head Neck Dis. 2017;134(4):253–258. doi:10.1016/j.anorl.2017.06.005
8.
HossenbaccusLLintonSGarveySEllisAK. Towards definitive management of allergic rhinitis: best use of new and established therapies. Allergy Asthma Clin Immunol. 2020;16(1):39. doi:10.1186/s13223-020-00436-y
9.
BousquetPJCombescureCNeukirchF, et al.Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. 2007;62(4):367–372. doi:10.1111/j.1398-9995.2006.01276.x
10.
JuniperEFGuyattGH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77–83. doi:10.1111/j.1365-2222.1991.tb00807.x
11.
NathanRAEcclesRHowarthPHSteinsvågSKTogiasA. Objective monitoring of nasal patency and nasal physiology in rhinitis. J Allergy Clin Immunol. 2005;115(3 Supplement):S442–S459. doi:10.1016/j.jaci.2004.12.015
12.
Martins de OliveiraGMRizzoJÂCamargosPASarinhoES. Are measurements of peak nasal flow useful for evaluating nasal obstruction in patients with allergic rhinitis?Rhinology. 2015;53(2):160–166. doi:10.4193/Rhin14.048
13.
WilsonDRTorres LimaMDurhamSR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis*. Allergy. 2005;60(1):4–12. doi:10.1111/j.1398-9995.2005.00699.x
14.
WeinerJMAbramsonMJPuyRM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. Br Med J. 1998;317(7173):1624. doi:10.1136/bmj.317.7173.1624
15.
NurmatovUDhamiSArasiS, et al.Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy. 2017;72(11):1597–1631. doi:10.1111/all.13201
16.
LiberatiAAltmanDGTetzlaffJ, et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. PLoS Med6(7): e1000100. 2009:1756–1833.
17.
KimJHLeeJHYeYM, et al.Efficacy and safety of sublingual immunotherapy in elderly rhinitis patients sensitized to house dust mites. Allergy Asthma Immunol Res. 2018;10(6):675–685. doi:10.4168/aair.2018.10.6.675
18.
LocksRBDos SantosKda SilvaJ. Quality of life in patients with allergic rhinitis: a clinical trial comparing the use of bilastine versus loratadine. Clin Otolaryngol. 2017;42(2):218–224. doi:10.1111/coa.12695
19.
EllisAKSolimanMSteacyL, et al.The allergic rhinitis - clinical investigator collaborative (AR-CIC): nasal allergen challenge protocol optimization for studying AR pathophysiology and evaluating novel therapies. Allergy Asthma Clin Immunol. 2015;11(1):16–16. doi:10.1186/s13223-015-0082-0
20.
MeltzerEOWallaceDDykewiczMShneyerL. Minimal clinically important difference (MCID) in allergic rhinitis: agency for healthcare research and quality or anchor-based thresholds?J Allergy Clin Immunol Pract. 2016;4(4):682–688. doi:10.1016/j.jaip.2016.02.006
21.
JuniperEFGuyattGHGriffithLEFerriePJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol. 1996;98(4):843–845. doi:10.1016/S0091-6749(96)70135-5
22.
Chin DMGMalekJPrattESacksRSnidvongsKHarveyR. Nasal peak inspiratory flow (NPIF) as a diagnostic tool for differentiating decongestable from structural nasal obstruction. Rhinology. 2014;52(2):116–121. doi:10.4193/Rhin13.126
23.
TimperleyDSAStowNMarcellsGNHarveyRJ. Minimal clinically important differences in nasal peak inspiratory flow. Rhinology. 2011;49(1):37–40. doi:10.4193/Rhino10.097
HigginsJPThomasJChandlerJCumpstonMLiTPageMJWelchVA (eds). Cochrane handbook for systematic reviews of interventions version 6.1. Cochrane; updated September2020. www.training.cochrane.org/handbook
26.
BorensteinMHedgesLVHigginsJPTRothsteinHR. An introduction to meta-analysis. In: Introduction to meta-analysis. John Wiley & Sons, Ltd; 2009:1–49.
27.
DerSimonianRLairdN. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
28.
EggerMSmithGDSchneiderMMinderC. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315(7109):629–634.
29.
SterneJAEggerM. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001 Oct;54(10):1046–1055.
30.
LeeDKGrayRDRobbFMFujiharaSLipworthBJ. A placebo-controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis. Clin Exp Allergy. 2004;34(4):646–649. doi:10.1111/j.1365-2222.2004.1903.x
31.
GuilemanyJMGarcia-PineroAAlobidI, et al.The loss of smell in persistent allergic rhinitis is improved by levocetirizine due to reduction of nasal inflammation but not nasal congestion (the CIRANO study). Int Arch Allergy Immunol. 2012;158(2):184–190. doi:10.1159/000331329
32.
CarusoMCibellaFEmmaR, et al.Basophil biomarkers as useful predictors for sublingual immunotherapy in allergic rhinitis. Int Immunopharmacol. 2018 Jul;60(1):50–58. doi:10.1016/j.intimp.2018.04.034
33.
RevickiDHaysRDCellaDSloanJ. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–109. doi:10.1016/j.jclinepi.2007.03.012
34.
SeresirikachornKMullolJLimitlaohaphanKAsvapoositkulVSnidvongsK. Leukotriene receptor antagonist addition to intranasal steroid: systematic review and meta-analysis. Rhinology. 2021;59(1):2–9.
35.
FengSFanYLiangZMaRCaoW. Concomitant corticosteroid nasal spray plus antihistamine (oral or local spray) for the symptomatic management of allergic rhinitis. Eur Arch Oto-Rhino-Laryngol. 2016;273(11):3477–3486. doi:10.1007/s00405-015-3832-1
36.
DuKQingHZhengMWangXZhangL. Intranasal antihistamine is superior to oral H1 antihistamine as an add-on therapy to intranasal corticosteroid for treating allergic rhinitis. Ann Allergy Asthma Immunol. 2020;125(5):589–596.e3. doi:10.1016/j.anai.2020.06.038
37.
BarnesMLVaidyanathanSWilliamsonPALipworthBJ. The minimal clinically important difference in allergic rhinitis. Clin Exp Allergy. 2010;40(2):242–250. doi:10.1111/j.1365-2222.2009.03381.x
38.
KlimekLBachertCPfaarO, et al.ARIA Guideline 2019: treatment of allergic rhinitis in the German health system. Allergol Select. 2019;3(1):22–50.
39.
MygindNNielsenLPHoffmannH-J, et al.Mode of action of intranasal corticosteroids. J Allergy Clin Immunol. 2001;108(1 Supplement):S16–S25. doi:10.1067/mai.2001.115561
40.
AchillesNPaschNLintermannASchröderWMösgesR. Computational fluid dynamics: a suitable assessment tool for demonstrating the antiobstructive effect of drugs in the therapy of allergic rhinitis. Acta Otorhinolaryngol Ital. 2013;33(1):36–42.
41.
Juel-BergNDarlingPBolvigJ, et al.Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: a systematic review and meta-analysis. Am J Rhinol Allergy. 2017;31(1):19–28. doi:10.2500/ajra.2016.30.4397
42.
NielsenLPDahlR. Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis: a review of randomized, controlled trials. Am J Respir Med. 2003;2(1):55–65. doi:10.1007/BF03256639
43.
MeltzerEOCaballeroFFromerLMKrouseJHScaddingG. Treatment of congestion in upper respiratory diseases. Int J Gen Med. 2010;3(1)69–91.
44.
CrownWHOlufadeASmithMWNathanR. Seasonal versus perennial allergic rhinitis: drug and medical resource use patterns. Value Health. 2003;6(4):448–456. doi:10.1046/j.1524-4733.2003.64231.x
45.
WallaceDVDykewiczMSOppenheimerJPortnoyJMLangDM. Pharmacologic treatment of seasonal allergic rhinitis: synopsis of guidance from the 2017 joint task force on practice parameters. Ann Intern Med. 2017;167(12):876–881. doi:10.7326/M17-2203
46.
RatnerPHHampelFVan BavelJ, et al.Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100(1):74–81. doi:10.1016/s1081-1206(10)60408-5
BruntonSNelsonHSBernsteinDILawtonSLuSNolteH. Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma. Postgrad Med. 2017;129(6):581–589. doi:10.1080/00325481.2017.1308208
49.
NelsonHS. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective?J Allergy Clin Immunol Pract. 2014;2(2):144–149.
50.
NelsonHCartierSAllen-RameyFLawtonSCalderonMA. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy. J Allergy Clin Immunol Pract. 2015;3(2):256–266.
51.
TieKMillerCZanationAMEbertCSJr. Subcutaneous versus sublingual immunotherapy for adults with allergic rhinitis: a systematic review with meta-analyses. Laryngoscope. 2021. Epub ahead of print. doi:10.1002/lary.29586
Starling-SchwanzRPeakeHLSalomeCM, et al.Repeatability of peak nasal inspiratory flow measurements and utility for assessing the severity of rhinitis. Allergy. 2005;60(6):795–800. doi:10.1111/j.1398-9995.2005.00779.x
54.
TeixeiraRUFZappeliniCEMAlvesFSda costaEA. Peak nasal inspiratory flow evaluation as an objective method of measuring nasal airflow. Braz J Otorhinolaryngol. 2011;77(4):473–480. doi:10.1590/s1808-86942011000400011
55.
KjærgaardTCvancarovaMSteinsvågSK. Does nasal obstruction mean that the nose is obstructed?Laryngoscope. 2008;118(8):1476–1481. doi:10.1097/MLG.0b013e318173a025
TaNHGaoJPhilpottC. A systematic review to examine the relationship between objective and patient-reported outcome measures in sinonasal disorders: recommendations for use in research and clinical practice. Int Forum Allergy Rhinol. 2021 May;11(5):910–923. doi:10.1002/alr.22744
58.
NeighbourHSolimanMSteacyLM, et al.The allergic rhinitis clinical investigator collaborative (AR-CIC): verification of nasal allergen challenge procedures in a study utilizing an investigational immunotherapy for cat allergy. Clin Transl Allergy. 2018;8:15. doi:10.1186/s13601-018-0198-7
